Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Santiago de Compostela (64)

2024

  1. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 199

  2. Edoxaban treatment in a post-infarction experimental model

    European Journal of Pharmacology, Vol. 962

  3. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

    Pharmaceuticals, Vol. 17, Núm. 2

  4. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

    Pharmaceutics, Vol. 16, Núm. 1

  5. Towards Precision Medicine in Clinical Practice: Alinity C vs. UHPLC-MS/MS in Plasma Aripiprazole Determination

    Pharmaceutics, Vol. 16, Núm. 1

  6. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. A continuous in silico learning strategy to identify safety liabilities in compounds used in the leather and textile industry

    Archives of Toxicology, Vol. 97, Núm. 4, pp. 1091-1111

  2. Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy

    Pharmaceutics, Vol. 15, Núm. 8

  3. Association of cyclophilins and cardiovascular risk factors in coronary artery disease

    Frontiers in Physiology, Vol. 14

  4. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  5. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence

    Pharmaceutics, Vol. 15, Núm. 11

  6. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  7. Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling

    European Journal of Medicinal Chemistry, Vol. 252

  8. Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial

    Pharmaceutics, Vol. 15, Núm. 2

  9. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

    Pharmaceutics, Vol. 15, Núm. 11

  10. Estudio farmacocinético de adalimumab intravítreo en un modelo de rata con uveítis mediante PET

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  11. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

    Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34

  12. Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages

    Drug Delivery and Translational Research, Vol. 13, Núm. 7, pp. 1896-1911

  13. NEmecum: digital tool for assisting in the prescription and dispensing of enteral nutrition formulas and infant preparations

    Nutricion Hospitalaria, Vol. 40, Núm. 5, pp. 924-933

  14. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review

    Pharmaceutics, Vol. 15, Núm. 3